Market Size of Sulphonamides Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 4.10 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Sulphonamides Market Analysis
The sulphonamides market is anticipated to record a CAGR of nearly 4.1% over the forecast period.
The COVID-19 pandemic had a substantial impact on the market due to supply chain disruptions and pandemic-related restrictions worldwide. However, initially, many antibiotics were used to treat COVID-19, which were widely prescribed and studied as the COVID-19 remedy. During the COVID-19 outbreak, antibiotics were used to improve public health and decrease the potential of other infectious exposures. An article published by Bioorganic & Medicinal Chemistry Letters in January 2021 stated that a novel class of cyclic sulfonamide derivatives acted as a promising new template for SARS-CoV-2 inhibitors using structural activity relationship optimization, viral inhibitory assays, cytotoxicity assays, and pharmacokinetic studies. Thus, the sulphonamides market is expected to grow due to an increasing number of studies on various sulfonamide derivatives used to treat COVID-19 infections.
Certain factors that are driving the market's growth include the increasing prevalence of chronic diseases worldwide and growing R&D activities in pharmaceutical companies. As per an article published by JEADV in March 2022, more than 94 million Europeans complain of uncomfortable skin sensations like itching, burning, or dryness. The most frequently reported conditions were fungal skin infections (8.9%), acne (5.4%), and atopic dermatitis or eczema (5.5%). Alopecia, acne, eczema, and rosacea were more common in women, whereas men were more likely to suffer from psoriasis and sexually transmitted infections (STIs). Similarly, there is a high prevalence of the diverse range of skin infections, gastrointestinal tract (GIT) infections, urinary tract infections, and respiratory tract infections globally. For instance, as per the report published by Verywell Health in November 2022, urinary tract infection (UTI) is an infection of the urinary system, which can affect the bladder (cystitis), urethra (urethritis), or kidneys (pyelonephritis), and 6 in 10 women in the United States experienced a UTI.
There has been an upsurge in the usage of advanced technologies, such as high throughput, bioinformatics, and combinatorial chemistry, for better drug candidate identification. Drug discovery has evolved significantly with emerging technologies, helping the process become more refined, accurate, and less time-consuming. However, increasing side effects associated with the use of sulfa drugs and the availability of substitute drugs may hinder the market's growth over the forecast period.
